<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T00:46:11Z</responseDate>
  <request identifier="oai:figshare.com:article/34049102" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34049102</identifier>
        <datestamp>2026-10-01T17:42:48Z</datestamp>
        <setSpec>category_4</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_13</setSpec>
        <setSpec>category_14</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_128</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>category_134</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;The Top 100 Codependencies of MCL1 and MARCHF5 downloaded from the Cancer Dependency Map 23Q4.&lt;/p&gt;</dc:title>
          <dc:creator>Prasanth Viswanathan (10314782)</dc:creator>
          <dc:creator>Justine R. Bersonda (25157885)</dc:creator>
          <dc:creator>Jackson Gill (25157888)</dc:creator>
          <dc:creator>Alyssandra Navarro (25157891)</dc:creator>
          <dc:creator>Allison C. Farrar (25157894)</dc:creator>
          <dc:creator>Thomas Caldarera (25157897)</dc:creator>
          <dc:creator>Andrew Murphy (341397)</dc:creator>
          <dc:creator>Daniel Dunham (25157900)</dc:creator>
          <dc:creator>Karl W. Boehme (11384016)</dc:creator>
          <dc:creator>Mark Manzano (25157903)</dc:creator>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Molecular Biology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Hematology</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>Virology</dc:subject>
          <dc:subject>systems biology approach</dc:subject>
          <dc:subject>regulating mitochondrial homeostasis</dc:subject>
          <dc:subject>primary effusion lymphoma</dc:subject>
          <dc:subject>immunoprecipitation experiments show</dc:subject>
          <dc:subject>endogenous reciprocal co</dc:subject>
          <dc:subject>emerging clinical relevance</dc:subject>
          <dc:subject>cell viability due</dc:subject>
          <dc:subject>newly appreciated interaction</dc:subject>
          <dc:subject>causes several malignancies</dc:subject>
          <dc:subject>unexpected genetic interaction</dc:subject>
          <dc:subject>findings thus provide</dc:subject>
          <dc:subject>div &gt;&lt; p</dc:subject>
          <dc:subject>marchf5 oncogenes may</dc:subject>
          <dc:subject>pel cells suggesting</dc:subject>
          <dc:subject>mcl1 motivated us</dc:subject>
          <dc:subject>genetic interaction</dc:subject>
          <dc:subject>tumor cells</dc:subject>
          <dc:subject>causes resistance</dc:subject>
          <dc:subject>thus investigated</dc:subject>
          <dc:subject>therapeutic potential</dc:subject>
          <dc:subject>survival role</dc:subject>
          <dc:subject>significant increase</dc:subject>
          <dc:subject>protein complex</dc:subject>
          <dc:subject>previously shown</dc:subject>
          <dc:subject>pel ).</dc:subject>
          <dc:subject>mechanistic link</dc:subject>
          <dc:subject>kaposi ’</dc:subject>
          <dc:subject>fitness advantage</dc:subject>
          <dc:subject>e3 ligase</dc:subject>
          <dc:subject>drug development</dc:subject>
          <dc:subject>dimerization activities</dc:subject>
          <dc:subject>crispr knockout</dc:subject>
          <dc:subject>combination therapies</dc:subject>
          <dc:subject>chemotherapy regimens</dc:subject>
          <dc:subject>attractive target</dc:subject>
          <dc:subject>associated herpesvirus</dc:subject>
          <dc:subject>apoptotic signal</dc:subject>
          <dc:subject>apoptotic activities</dc:subject>
          <dc:subject>antiviral signaling</dc:subject>
          <dc:description>&lt;p&gt;The Top 100 Codependencies of MCL1 and MARCHF5 downloaded from the Cancer Dependency Map 23Q4.&lt;/p&gt;</dc:description>
          <dc:date>2026-10-01T17:54:28Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1371/journal.ppat.1014665.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_p_The_Top_100_Codependencies_of_MCL1_and_MARCHF5_downloaded_from_the_Cancer_Dependency_Map_23Q4_p_/34049102</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
